Cargando…

Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1

OBJECTIVE—We examined metabolic changes in the period immediately after the diagnosis of type 1 diabetes and in the period leading up to its diagnosis in Diabetes Prevention Trial–Type 1 (DPT-1) participants. RESEARCH DESIGN AND METHODS—The study included oral insulin trial participants and parenter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosenko, Jay M., Palmer, Jerry P., Rafkin-Mervis, Lisa, Krischer, Jeffrey P., Cuthbertson, David, Matheson, Della, Skyler, Jay S.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2008
Materias:	Pathophysiology/Complications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2571043/ https://www.ncbi.nlm.nih.gov/pubmed/18650369 http://dx.doi.org/10.2337/dc08-0935

Ejemplares similares

Incident Dysglycemia and Progression to Type 1 Diabetes Among Participants in the Diabetes Prevention Trial–Type 1
por: Sosenko, Jay M., et al.
Publicado: (2009)

Distribution of C-Peptide and Its Determinants in North American Children at Risk for Type 1 Diabetes
por: Xu, Ping, et al.
Publicado: (2014)

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2010)

TCF7L2 Genetic Variants Contribute to Phenotypic Heterogeneity of Type 1 Diabetes
por: Redondo, Maria J., et al.
Publicado: (2018)

Glucose Excursions Between States of Glycemia With Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1)
por: Sosenko, Jay M., et al.
Publicado: (2010)

Association of HLA-DQ Heterodimer Residues −18β and β57 With Progression From Islet Autoimmunity to Diabetes in the Diabetes Prevention Trial–Type 1
por: Zhao, Lue Ping, et al.
Publicado: (2022)

Acceleration of the Loss of the First-Phase Insulin Response During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 Participants
por: Sosenko, Jay M., et al.
Publicado: (2013)

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for Improving the Accuracy of the Risk Classification of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2014)

Impact of Islet Autoimmunity on the Progressive β-Cell Functional Decline in Type 2 Diabetes
por: Brooks-Worrell, Barbara M., et al.
Publicado: (2014)

The Application of the Diabetes Prevention Trial–Type 1 Risk Score for Identifying a Preclinical State of Type 1 Diabetes
por: Sosenko, Jay M., et al.
Publicado: (2012)

Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes
por: Sims, Emily K., et al.
Publicado: (2019)

Insulin Administration and Rate of Glucose Appearance in People With Type 1 Diabetes
por: Pennant, Mary E., et al.
Publicado: (2008)

Serum Trypsinogen Levels in Type 1 Diabetes
por: Li, Xia, et al.
Publicado: (2017)

Prevalence of and Risk Factors for Diabetic Peripheral Neuropathy in Youth With Type 1 and Type 2 Diabetes: SEARCH for Diabetes in Youth Study
por: Jaiswal, Mamta, et al.
Publicado: (2017)

Inflammation and Progressive Nephropathy in Type 1 Diabetes in the Diabetes Control and Complications Trial
por: Lin, Julie, et al.
Publicado: (2008)

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
por: Orban, Tihamer, et al.
Publicado: (2009)

Biomarkers of tubulointerstitial damage and function in type 1 diabetes
por: de Boer, Ian H, et al.
Publicado: (2017)

Clinical and biochemical profile of 786 sequential episodes of diabetic ketoacidosis in adults with type 1 and type 2 diabetes mellitus
por: Ooi, Emma, et al.
Publicado: (2021)

Incidence of severe hypoglycemia in children with type 1 diabetes in the Nordic countries in the period 2008–2012: association with hemoglobin A (1c) and treatment modality
por: Birkebaek, NH, et al.
Publicado: (2017)

Cerebral small-vessel disease is associated with the severity of diabetic retinopathy in type 1 diabetes
por: Eriksson, Marika I, et al.
Publicado: (2021)

Cardiovascular autonomic neuropathy and the impact on progression of diabetic kidney disease in type 1 diabetes
por: Bjerre-Christensen, Theis, et al.
Publicado: (2021)

Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46)
por: Yokoyama, Hiroki, et al.
Publicado: (2018)

Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data
por: Greenbaum, Carla J., et al.
Publicado: (2012)

Insulin Gene Mutations as Cause of Diabetes in Children Negative for Five Type 1 Diabetes Autoantibodies
por: Bonfanti, Riccardo, et al.
Publicado: (2009)

Using in vivo corneal confocal microscopy to identify diabetic sensorimotor polyneuropathy risk profiles in patients with type 1 diabetes
por: Lewis, Evan J H, et al.
Publicado: (2017)

The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
por: Sosenko, Jay M., et al.
Publicado: (2013)

Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial
por: Lachin, John M., et al.
Publicado: (2017)

Spatial variations in gut permeability are linked to type 1 diabetes development in non-obese diabetic mice
por: Joesten, William C, et al.
Publicado: (2019)

Retinal Arteriolar Dilation Predicts Retinopathy in Adolescents With Type 1 Diabetes
por: Cheung, Ning, et al.
Publicado: (2008)

Impaired exocrine pancreatic function in different stages of type 1 diabetes
por: Dozio, Nicoletta, et al.
Publicado: (2021)

Histological and transcriptional characterization of the pancreatic acinar tissue in type 1 diabetes
por: Granlund, Louise, et al.
Publicado: (2021)

A1C Variability and the Risk of Microvascular Complications in Type 1 Diabetes: Data from the Diabetes Control and Complications Trial
por: Kilpatrick, Eric S., et al.
Publicado: (2008)

Complication characteristics between young-onset type 2 versus type 1 diabetes in a UK population
por: Song, Soon H
Publicado: (2015)

A Longitudinal Study of GAD65 and ICA512 Autoantibodies During the Progression to Type 1 Diabetes in Diabetes Prevention Trial–Type 1 (DPT-1) Participants
por: Sosenko, Jay M., et al.
Publicado: (2011)

Residual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetes
por: Wellens, Martine J, et al.
Publicado: (2021)

Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study
por: Sosenko, Jay M., et al.
Publicado: (2011)

Burden of Urological Complications in Men and Women With Long-standing Type 1 Diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort
por: Wessells, Hunter, et al.
Publicado: (2018)

Erratum. Validation of the Diabetes Prevention Trial–Type 1 Risk Score in the TrialNet Natural History Study. Diabetes Care 2011;34:1785–1787
por: Sosenko, Jay M., et al.
Publicado: (2018)

Association Between Impaired Cardiovascular Autonomic Function and Hypoglycemia in Patients With Type 1 Diabetes
por: Jaiswal, Mamta, et al.
Publicado: (2014)

Islet Transplantation Stabilizes Hemostatic Abnormalities and Cerebral Metabolism in Individuals With Type 1 Diabetes
por: D’Addio, Francesca, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_24febqjm5resv2bcl8h7iir2ad